Skip to main content
. 2022 Jan 29;3(1):101143. doi: 10.1016/j.xpro.2022.101143

Figure 3.

Figure 3

In vitro characterization of implants

(A) Cy5.5/PLGA implants used in this specific use case.

(B) In vitro release profile of Cy5.5 from implant (data displayed as mean ± SEM; n = 3) in PBS supplemented with bovine serum albumin (0.1%, w/v) over 7 days reveals the sustained drug release. At 1 week, 0.6 ng of dye was detected in the buffer, for a cumulative release percentage of 3.4% (based on initial calculation of 18 ng Cy5.5 in intact implant). See also Figure S1.